
-
Trump's fossil fuel agenda challenged in youth climate suit
-
PSG fear impact of injuries as they put Champions League title on the line
-
US Senate confirms Trump aide to Fed as politics loom over rate meeting
-
Papua New Guinea, Australia will commit to mutual defence
-
Trash, mulch and security: All jobs for troops in Washington
-
NFL legend Brady to play in March flag football event at Riyadh
-
Lower US tariffs on Japan autos to take effect Tuesday
-
US strikes second alleged Venezuelan drug boat as tensions mount
-
Protesting Peru residents block trains to Machu Picchu
-
US strikes another alleged Venezuelan drug boat as tensions rise
-
White House vows to take on left-wing 'terror' movement after Kirk killing
-
Brazil's Amazon lost area the size of Spain in 40 years: study
-
US Senate poised to advance Trump aide's appointment at Fed
-
Sri Lanka survive Hong Kong scare for four wicket Asia Cup win
-
Arab, Muslim leaders urge review of Israel ties after Qatar attack
-
Mbappe 'not anxious' over Champions League goal as Bellingham returns
-
Huge pot of Nigerian jollof rice sets Guinness record
-
Heartbreak will help Arsenal's Champions League charge: Arteta
-
Europe stumped by Trump demands over Russia sanctions
-
Cycling fears spread of race-halting protests after Vuelta chaos
-
US, China reach 'framework' deal on TikTok ownership
-
'With our fists if necessary': Venezuelans prepare to defend homeland against potential US invasion
-
Duplantis thrives on Tokyo energy to break world record again
-
Ex-France defender Umtiti calls time on club career
-
One in six US parents rejecting standard vaccine schedule: poll
-
Sheffield Utd appoint Wilder for third managerial spell
-
UAE hammer Oman in Asia Cup to keep Super Four hopes alive
-
Activists on trial as France debates right to die
-
Duplantis reaches new heights, Beamish makes Kiwi history at worlds
-
Frank relishing Champions League debut with Spurs
-
Spanish PM calls for Israel to be barred from international sport
-
UK aristocrat, partner get 14 years for baby daughter's manslaughter
-
US says 'framework' deal with China on TikTok ownership
-
Shootings 'unjustified' in Bloody Sunday killings, Belfast court hears
-
Three French women accused of IS links go on trial
-
'Stoked' Beamish stuns tearful El Bakkali for world steeplechase gold
-
Israel attack aimed to halt Gaza talks, Qatar emir tells emergency summit
-
Stocks push higher ahead of expected US rate cut
-
Duplantis sets new pole vault record as retains world title
-
US announces 'framework' TikTok deal with China
-
Kiwi Beamish stuns tearful El Bakkali for world steeplechase gold
-
Mbappe not anxious over Champions League wait: Alonso
-
Japan medal hope Muratake relishing stage at Tokyo worlds
-
Right-to-die activists on trial in France as lawmakers debate end-of-life bill
-
Singing British hurdler Donovan in tune on world debut
-
'Multiple concussions' force France lock Willemse to retire
-
Athletic 'not afraid' of Arsenal on Champions League return: Inaki Williams
-
Hatton's family speak of 'immeasurable' loss after boxer's death
-
Rubio promises 'unwavering support' for Israel in Gaza goals
-
Stocks diverge ahead of expected US rate cut

From Covid to cancer: High hopes for Nobel mRNA vaccines
The coronavirus pandemic brought global renown to the mRNA technology that underpins vaccines from Pfizer/BioNTech and Moderna, and on Monday earned a Nobel Prize for two scientists who have been key to its development.
Katalin Kariko of Hungary and Drew Weissman of the United States won the Nobel Medicine Prize for their work on "nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19".
These types of jabs are new but researchers have been working for decades to try to figure out how to use messenger RNA (ribonucleic acid) for other vaccinations and to treat illnesses from AIDS to cancer.
- How does it work? -
Messenger RNA's job in the body is to help deliver specific instructions from DNA to cells.
In the case of the Pfizer/BioNTech and Moderna jabs, lab-generated mRNA tells human cells to create antigens -- proteins that are similar to ones found in the Covid-19 virus.
Thanks to those antigens, a person's immune system learns how to fight the virus and neutralise Covid if it enters the body.
After the cells create these proteins, the body breaks down the mRNA instructions and gets rid of them.
Such direct communication with cells is revolutionary -- classic vaccines aimed to provoke an immune response by injecting a neutralised form of a virus or antigens into the system.
- Where did this come from? -
The first big breakthrough, in the late 1970s, was in using mRNA to make test-tube cells produce proteins.
A decade later, scientists were able to get the same results in mice, but mRNA still had two major drawbacks as a medical tool.
For one thing, cells in live animals resisted synthetic mRNA, provoking a dangerous immune response.
On top of that, mRNA molecules are fragile, making them difficult to deliver to the system without altering them.
In 2005, Kariko and Weissman of Penn State University published a groundbreaking study showing that a lipid -- or fat molecule -- envelope could safely deliver mRNA without negative effects.
The research caused a buzz in the pharmaceutical community and start-ups dedicated to mRNA therapies began to pop up around the world.
- What else can mRNA do? -
Scientists have worked on developing mRNA jabs for illnesses like seasonal flu, rabies and Zika, as well as those that have remained vaccine-resistant until now, including malaria and AIDS.
Researchers have also started testing personalised treatments on cancer patients, using samples of the proteins in their tumours to create specialised mRNA.
This then triggers the immune system to target specific cancer cells.
"The mRNA platform is versatile," University of Pennsylvania biochemist Norbert Pardi told AFP. "Any protein can be encoded as mRNA so there are many potential applications."
G.Stevens--AMWN